Controlled Substances

Congress recently extended Medicare telehealth flexibilities that waive a requirement for an in-person visit before a patient can receive mental health services via telehealth.

As healers, we are most comfortable and confident when we can rely on the long-established armamentarium of countless medications created by the American pharmaceutical industry.

The U.S. Drug Enforcement Administration is proposing to reclassify marijuana as a less dangerous drug, moving it from a Schedule I to Schedule III substance.

The U.S. Drug Enforcement Agency, or DEA, has announced a temporary extension of prescribing flexibility for controlled substances over telehealth, which was set to expire on May 11.

The American Psychiatric Association has recommended the Drug Enforcement Administration ensure access to buprenorphine and other controlled drugs through telehealth to combat the opioid epidemic and the national mental health crisis.

The U.S. Drug Enforcement Administration, or DEA, has proposed permanent changes to rules on the prescribing of controlled substances through telehealth. The new rules would take effect when the COVID-19 public health emergency ends in May.